Vabomere (Meropenem/Vaborbactam) Patent Expiration, LOE Window & CMS Spending

Vabomere (Meropenem/Vaborbactam) by Rempex A Wholly Owned Sub Of Melinta Therapeutics: FDA Orange Book core substance LOE 2031-08-29 (last listed 2039-04-06), 0 AB generics, $1.5M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRempex A Wholly Owned Sub Of Melinta Therapeutics
FDA Application & PathwayN209776 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2031-08-29
Last Listed Patent or Exclusivity Date2039-04-06
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.5M
2024 Medicare Part D Spend$1.1M
2024 Medicaid Spend$342K
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 21.2% 2-yr change)